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Abstract: On 3 December 1967, Christiaan Barnard performed the first heart transplantation in the world
at Groote Schuur Hospital in Cape Town, South Africa. In the succeeding months, heart transplantations
in the USA, Asia and Europe followed. On 14 April 1969, Aring;ke Senning successfully accomplished the
first heart transplantation in Switzerland at the former Cantonal Hospital in Zurich. In the summer of
1969, he undertook a second heart transplantation. Although the surgical procedure went well technically,
both patients died within weeks to months after transplantation. Causes of death were infection in
the first and rejection in the second patient. Senningrsquo;s colleagues around the world had similar
experiences. Survival after heart transplantation was unacceptably low. The heart transplant community
recognised the lack of knowledge about immunological processes and appropriate immunosuppressive
regimens as underlying reason for the early deaths. Most transplant centres decided to refrain from heart
transplantation until sufficient immunological insight became available. After the introduction of the new
immunosuppressive drug ciclosporin into the clinic and the availability of tools to monitor rejection in the
early 1980s, heart transplant programmes were restarted all over the world. The legal recognition of brain
death allowed procurement of donor hearts without exposure to warm ischaemia, and the principle of cold
storage enabled prolongation of ischaemia time and acceptance of donors in distant hospitals, resulting in
enlargement of the donor pool. In Switzerland, Marko Turina resumed heart transplantation in 1985 at
Senningrsquo;s former workplace in Zurich. The number of heart transplants in Switzerland and in the
world grew rapidly because the outcome markedly improved. Particularly over the long-term, survival
in Zurich surpassed the outcome worldwide. Zurich created internationally recognised milestones such
as transplantation of patients with grown-up congenital heart disease, the implementation of the bicaval
instead of the right atrial anastomosis during the transplant procedure and the dual transplantation of
one heart. Since the middle of the 1990s, however, the number of heart transplants has plateaued, mainly
because of donor shortage. The current era is characterised by efforts to increase the number of donors.
The utilisation of marginal donors, the change from informed to presumed consent for organ donation
and donation after cardiocirculatory-determined death have been proposed to augment the donor pool.
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Summary
On 3 December 1967, Christiaan Barnard performed the
first heart transplantation in the world at Groote Schuur
Hospital in Cape Town, South Africa. In the succeeding
months, heart transplantations in the USA, Asia and Eu-
rope followed. On 14 April 1969, Åke Senning successfully
accomplished the first heart transplantation in Switzerland
at the former Cantonal Hospital in Zurich. In the summer
of 1969, he undertook a second heart transplantation. Al-
though the surgical procedure went well technically, both
patients died within weeks to months after transplantation.
Causes of death were infection in the first and rejection in
the second patient. Senning’s colleagues around the world
had similar experiences. Survival after heart transplanta-
tion was unacceptably low. The heart transplant communi-
ty recognised the lack of knowledge about immunological
processes and appropriate immunosuppressive regimens
as underlying reason for the early deaths. Most transplant
centres decided to refrain from heart transplantation until
sufficient immunological insight became available. After
the introduction of the new immunosuppressive drug ci-
closporin into the clinic and the availability of tools to
monitor rejection in the early 1980s, heart transplant pro-
grammes were restarted all over the world. The legal
recognition of brain death allowed procurement of donor
hearts without exposure to warm ischaemia, and the prin-
ciple of cold storage enabled prolongation of ischaemia
time and acceptance of donors in distant hospitals, re-
sulting in enlargement of the donor pool. In Switzerland,
Marko Turina resumed heart transplantation in 1985 at
Senning’s former workplace in Zurich. The number of
heart transplants in Switzerland and in the world grew
rapidly because the outcome markedly improved. Particu-
larly over the long-term, survival in Zurich surpassed the
outcome worldwide. Zurich created internationally recog-
nised milestones such as transplantation of patients with
grown-up congenital heart disease, the implementation of
the bicaval instead of the right atrial anastomosis during
the transplant procedure and the dual transplantation of
one heart. Since the middle of the 1990s, however, the
number of heart transplants has plateaued, mainly be-
cause of donor shortage. The current era is characterised
by efforts to increase the number of donors. The utilisation
of marginal donors, the change from informed to pre-
sumed consent for organ donation and donation after car-
diocirculatory-determined death have been proposed to
augment the donor pool.
Keywords: heart transplantation, 50th anniversary in
Switzerland, brain death, donation after cardiocirculatory
determined death, cyclosporine, rejection, infection, mora-
torium, cold storage, bicaval anastomosis
The first heart transplantation in the world
Based on the leading work of Norman Shumway and col-
leagues [1–3], the first heart transplantation worldwide
was realised by Christiaan Barnard at Groote Schuur Hos-
pital in Cape Town, South Africa, on 3 December 1967.
The 53-year-old Louis Washkansky received the heart of
25-year-old Denise Darvall, who suffered from severe
brain injury due to a traffic accident [1, 2]. In 2017, on
the 50th anniversary of the worldwide first heart transplan-
tation, DKC Cooper, a contemporary surgical colleague
of Barnard in South Africa, portrayed the circumstances
around this epochal event [1]. At that time, brain death was
not yet recognised legally. According to the law in South
Africa, a patient could be considered dead when he or she
was declared dead by a physician. Barnard took advantage
of this statement and interpreted it such that he could use
brain death as a criterion for declaring a patient dead. Nev-
ertheless his plan was, according to the ethical rules set by
the Groote Schuur authorities, to wait until complete heart
arrest before removing the heart for transplant, because he
did not want to be caught up in legal affairs. Barnard also
obeyed another ethical rule of the Groote Schuur authori-
ties in the politically charged apartheid atmosphere, which
required that both donor and recipient be of white race [3].
After the local neurosurgeons declared the accident victim
brain dead and her father agreed to donation, Barnard de-
cided to do the transplant [2]. Approximately 6 minutes af-
ter ventilation was discontinued, the heart went into ven-
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tricular fibrillation, which was considered functional heart
arrest. The chest was opened, and a heart-lung machine
was connected to cool down the heart with cold oxygenat-
ed blood and reduce the duration of warm ischaemic injury.
Ischaemic heart arrest was 8 minutes in normothermia and
14 minutes at 22°C [3]. The heart was excised and trans-
ferred to the adjacent operating room where the recipient
was already prepared. Thus, the heart for the first heart
transplantation in the world was explanted from a “non-
heart-beating donor” or, as it is called today, a “donation
after circulatory-determined death (DCD) donor” [4]. The
heart was implanted into the recipient according to the
technique described by Shumway and Lower [5]. Only at
the third attempt could the patient be weaned successfully
from extracorporeal circulation after a reperfusion time of
3 hours and 41 minutes [3]. This might have been a result
of insufficient myocardial protection due to the obligato-
ry wait for circulatory standstill of the donor heart and the
recipient’s severe pulmonary hypertension at 11.5 Wood
units, which would today be considered an absolute con-
traindication for heart transplantation [3]. Another interest-
ing detail of the operative procedure was that anaesthesiol-
ogy monitoring for cardiac surgery in Groote Schuur was
rudimentary. Blood pressure was measured with a mer-
cury manometer and central venous pressure using a water
manometer. Blood gas analysis only allowed measurement
of pCO2 and pH, but not pO2 [3]. Surprisingly, nobody
photographed or filmed the operation for which the media
would later have offered millions [3].
The patient made a rapid recovery during the first postop-
erative week. In the second week, he developed pulmonary
infiltrates on chest x-ray. Since they were misinterpreted as
a sign of rejection and not recognised as an incipient infec-
tion, Barnard decided to increase the immunosuppressive
therapy. The condition of the patient rapidly deteriorated
and he died on day 18 after heart transplantation. The an-
tibiotic treatment which was started after pneumonia was
diagnosed came too late. The autopsy confirmed pneumo-
nia as cause of death. The heart showed no signs of rejec-
tion.
The first heart transplantations in the USA,
Asia and Europe
On 6 December 1967, three days after Barnard’s first heart
transplant worldwide, Adrian Kantrowitz performed the
first heart transplant in the USA at Maimonides Medical
Center in Brooklyn, New York [6]. The recipient was an
18-day-old male infant who received the heart of a 2-day-
old anencephalic male. The procedure was carried out in
hypothermia without the aid of the heart-lung machine. Al-
though the procedure was technically successful, the trans-
planted heart stopped beating after 7 hours. After Barnard
did his second heart transplant on 2 January 1968, which
was the third heart transplant worldwide [1], Norman
Shumway performed the first successful adult heart trans-
plant in the USA on 6 January 1968, at Stanford.
Shumway’s patient died after 15 days from liver and kid-
ney failure and internal bleeding [7]. Barnard’s second pa-
tient lived for almost 19 months, but then died from heart
failure due to graft atherosclerosis [1, 8].
On 5 February 1968, PK Sen performed the first heart
transplantation in Asia at King Edward Memorial Hospital
in Bombay [9]. In Europe, Christian Cabrol performed the
first heart transplantation on 27 April 1968, at the Hôpital
La Pitie Salpêtrière in Paris [10, 11]. Cabrol’s patient died
after 3 days from pulmonary embolism. Until the end of
the year 1968, 104 heart transplantations were done world-
wide [12].
The first heart transplantation in Switzerland
On 14 April 1969, Åke Senning performed the first heart
transplantation in Switzerland at the former Cantonal Hos-
pital in Zurich. It was the 126th heart transplantation in
the world. A 54-year-old patient received a heart from a
27-year-old donor who was victim of a traffic accident.
After the patient was declared dead by a multidisciplinary
professorial commission headed by the forensic pathol-
ogist and independent of the implant team of cardiac
surgery, consent for donation was obtained from the rel-
atives. Since the donor, who had a temperature of 31°C,
was haemodynamically unstable, he was connected to the
heart-lung machine and cooled down further. In the mean-
time, the heart was examined and considered suitable for
transplantation. Simultaneously, the recipient was taken on
the heart-lung machine in the adjacent operating room.
When the donor heart developed ventricular fibrillation,
it was excised and transported to the recipient’s operating
room. After removal of the recipient’s heart, the donor
heart was implanted. The implantation took less than 1
hour, the whole surgery lasted 2.5 hours and was technical-
ly successful [13].
In the press conference broadcast by Swiss television on
the same day, Senning emphasised the importance of the
multidisciplinary team approach with participation of al-
most every clinic of the hospital, which was what made the
heart transplantation possible (fig. 1) [13]. Senning stat-
ed that he did not do something particularly new. He just
did what the other heart transplant surgeons in the world
had done before, and what he and his team had practised
in the animal laboratory. The surgical technique of heart
transplantation was not more difficult than that of a rou-
tine heart operation, Senning said. At least five surgeons of
his team would have been able to perform the operation.
In preparation for the operation, one of his staff members
had previously visited Denton Cooley in Houston, where
he was able to observe 16–18 heart transplantations.
Senning also noted that the successful operation solved on-
ly the smallest problem. The biggest challenge would be
the evolving immunological processes between the recipi-
ent and the donor heart, which had to be addressed togeth-
er with the teams of the other clinics. He was optimistic
that the immunological experience gained from 50 kidney
transplants in Zurich would be of advantage in the manage-
ment of immunosuppression.
After an initial uneventful course, the patient suffered from
pneumonia which caused death 1 month after transplanta-
tion. In the summer of 1969, Senning performed the sec-
ond heart transplantation in Switzerland. The patient re-
covered well and was discharged home after a few weeks.
Three months after the transplant, he suddenly died while
working on his farm, most likely owing to acute rejection.
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The moratorium
The survival of the first 60 heart transplant patients world-
wide was unacceptably low. Only 81% survived more than
1 day after transplantation. One-month survival was just
50%. After 1 year, no more than 18% of patients were
alive [12]. Acute rejection and infection were the most fre-
quent causes of death. In the first 30 heart transplant pa-
tients in the USA, acute rejection accounted for 40% and
infection for 15% of deaths [12]. As a result of the fright-
ening deaths rates, the initial euphoria about heart trans-
plantation declined rapidly. After the enthusiastic 102 heart
transplants in 1968, the numbers worldwide decreased to
48 in 1969 and 18 in 1970 [11, 12]. In the light of the dis-
appointing results, the medical establishment, led by the
American Heart Association, called for a moratorium on
heart transplantation [7]. In February 1973, the Department
of Health in Britain issued a moratorium on further heart
transplants in the United Kingdom [12]. Almost all major
institutions complied, except Norman Shumway in Stan-
ford and Richard Lower at the Medical College of Vir-
ginia, who had developed the surgical technique of heart
transplantation together with Shumway during his time in
Stanford [5, 7, 14]. The Stanford team developed revised
protocols for patient selection, since many of the pioneers
had realised that the patients who had been selected for
transplantation were too sick to survive. Furthermore, the
crucial problem of monitoring and treating rejection was
approached. Following experimental studies in the dog,
Philip Caves at Stanford brought into clinical application
the bioptom, which could be inserted through the jugular
vein into the right ventricle to obtain pieces of the heart
muscle for pathological examination on rejection [15, 16].
This method, which went into clinical routine at Stanford
in 1973, made it possible to detect acute rejection earli-
er than it was previously possible, when the decrease of
electrocardiogram voltages was used for diagnosing rejec-
tion. Immunosuppression could now be intensified at an
earlier stage of acute rejection and, accordingly, be reduced
again in time, after the rejection had resolved and before
a potentially lethal infection could develop [12]. Margret
Billingham at Stanford developed a classification for rejec-
tion based on the number of infiltrating leucocytes and the
amount of damage to the cardiomyocytes [17–19]. On the
basis of her studies, the first grading system of cardiac al-
lograft rejection was later published in 1990 [20].
As a result of these advances, Shumway was able to im-
prove the outcome after heart transplantation considerably.
In the period from Shumway’s first heart transplant in 1968
until November 1980, the Stanford team achieved a re-
markable 1-year actuarial survival of 68% [21]. The break-
through in heart transplantation, however, came with the
availability of ciclosporin. Its immunosuppressive activi-
ty was discovered by Borel and Stähelin in the laborato-
ries of Sandoz in Basel, Switzerland [22, 23]. In 1980,
ciclosporin was introduced into the clinical programme
at Stanford, which improved outcomes significantly, with
1-year survival approaching 80% [14, 24, 25]. In Septem-
ber 1983, ciclosporin obtained approval by the FDA (Food
and Drug Administration of the USA), which paved the
way for worldwide clinical application of ciclosporin in
Figure 1: Åke Senning during the press conference held in the auditorium of the former Cantonal Hospital Zurich after the first successful
heart transplantation in Switzerland on 14 April 1969 (Source: SRF).
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transplantation medicine in general and in heart transplan-
tation in particular [26]. Survival following heart trans-
plantation improved significantly under the ciclosporin-
based immunosuppressive regimen [21].
In addition to the advances in patient management before
and after heart transplantation, as outlined above, the es-
tablishment of the brain death concept markedly con-
tributed to the improved outcomes. In 1968, the Ad Hoc
Committee of the Harvard Medical School to Examine the
Definition of Brain Death published a report which com-
prised the first formal definition of brain death [27, 28].
This report was the basis for establishing laws for the le-
gal recognition of brain death in most parts of the world.
In the US, the legal basis for declaration of brain death was
finalised in 1981 and published in a landmark article in the
Journal of the American Medical Association [14, 29].
The key advantage for organ explantation was that the
heart could be harvested without being exposed to warm
ischaemia. Before brain death was accepted as definition
of death, the heart could only be explanted after cessation
of the heartbeat, which was considered the precondition to
declare a patient dead. This, however, was associated with
a period of progressive deterioration and finally stagnation
of the circulation, which caused insufficient oxygen and
energy supply to the heart in a warm environment. This so-
called warm ischaemia is known to injure the heart with a
negative impact on outcome after transplantation [30]. In
brain dead donors, there is no need to wait for the cessa-
tion of the heartbeat. The beating heart can be arrested by
cold cardioplegia and subsequently stored on ice. This in-
duces a state of cold ischaemia, which is better tolerated by
the myocardium than warm ischaemia [31, 32]. Lower and
Shumway demonstrated in the laboratory in a dog mod-
el that a heart that was stored in 2–4°C saline for up to 7
hours could successfully be transplanted with normal phys-
iological function [33]. They were the first to prove this
concept in the clinic when they transplanted successful-
ly a heart that was exposed to cold storage for transporta-
tion from the donor hospital in the periphery of Stanford to
the recipient hospital [14]. This method of cold storage al-
lowed the donor pool to expand, since not only hearts from
in-house donors could be used, as had been practiced hith-
erto, but also those from peripheral hospitals [14, 34, 35].
Restart of heart transplantation
The advances in patient selection and management, mon-
itoring and treatment of rejection, as well as myocardial
preservation, resulted in improved outcomes following
heart transplantation [21]. This encouraged the global heart
transplant community to restart their programmes. The
number of heart transplants worldwide exponentially in-
creased from 322 in 1983 to almost 5000 in 1993 [36].
In Zurich, Marko Turina launched the restart of the heart
transplant programme in 1985. The number of heart trans-
plants rose from 2 in 1985 to 34 in 1989 (fig. 2). After
1994, the number of heart transplants decreased in Zurich,
as well as worldwide, mainly because of the increasing
shortage of suitable donors [36] (fig. 2). In recent years,
a slight increase in transplant numbers can be observed,
which may be in part explained by the success of cam-
paigns for donation and the acceptance for transplantation
of donor hearts with higher risk.
Under the guidance of Marko Turina, several achievements
in heart transplant surgery were accomplished in Zurich
with considerable international impact, such as heart trans-
plantation in patients with grown-up congenital heart dis-
Figure 2: Number of heart transplants in Zurich from restart of the programme in 1985 until 2018.
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ease (GUCH), the implementation of the bicaval instead
of the standard right atrial anastomosis, and the re-trans-
plantation of an already transplanted heart [37–39]. Al-
though little experience existed worldwide, Zurich com-
menced heart transplantation in GUCH patients in the late
1980s. Using a modified donor cardiectomy with extensive
length of the inflow and outflow tissues, the transplant pro-
cedure could be performed successfully without prosthet-
ic material. Complex malformations could be reconstruct-
ed by applying the additional tissue taken with the donor
heart such that the anatomically normal donor heart fitted
in the recipient [37]. The application of the bicaval anas-
tomosis as opposed to the right atrial anastomosis, which
was previously the standard technique developed by Lower
and Shumway, was associated with two advantages (fig. 3)
[38]. Since the sinus node was transplanted with the donor
heart, the need for pacemaker implantation decreased sig-
nificantly, and the transplantation of the complete right
atrium preserved its geometry, resulting in a significantly
reduced incidence of tricuspid regurgitation. The retrans-
plantation of an already transplanted heart in a second re-
cipient after the first recipient suffered from brain death
was recognised as world novelty and constituted a rational
solution in an era of organ shortage [39].
Outcome following heart transplantation steadily im-
proved, particularly in the early phase after transplantation.
This may be attributed to advances in the perioperative
Figure 3: Illustration of the two different surgical techniques for heart transplantation. Upper panel: the classic biatrial technique. Lower panel:
the modified bicaval technique.
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management by a multidisciplinary team and a decrease in
acute rejection episodes during the first year after trans-
plant [36]. One-year survival improved from 77% in the
1980s to 85% in the 2010s, and 10-year survival increased
from 63% to 75% in the same time period [36]. This trend
could also be observed in Zurich, with survival rates be-
ing superior to the worldwide outcomes reported by the
International Society for Heart and Lung Transplantation
(ISHLT), particularly over the long term. Previously, we
have analysed the long-term outcome of 133 patients trans-
planted in the first 7 years after restart of the programme in
1985 until 1991. We could show that 20-year actuarial sur-
vival was 55.6% (fig. 4), which surpasses the actual world-
wide 20-year survival rate of 22.8% reported in the latest
analysis of the ISHLT in 2018 [36, 40].
Current aspects of heart transplantation
Although heart transplantation evolved into a success story
over past decades, it faces some limitations in the current
era. Because of the shortage of donors, the number of heart
transplants has plateaued over the years in Switzerland and
internationally [36, 41, 42]. Various measures have been
proposed to enlarge the donor pool, such as the use of mar-
ginal donors and, most recently, the modification of the
consent for donation and the utilisation of “donation after
cardiocirculatory-determined death (DCD)” donors.
Conditions of marginal donors include primarily older age,
prolonged ischaemia time, left ventricular hypertrophy and
left ventricular dysfunction. Each of these factors has been
shown to increase the risk of inferior outcome after trans-
plantation [36, 43, 44]. However, there is notable evidence
that transplantation of marginal donor hearts may achieve
satisfying outcomes and, thus, is justifiable in order to
counteract the donor shortage [45]. The appropriate man-
agement of the marginal donor in the period before explan-
tation is the precondition for successful results [46].
The impact of the mode of consent for donation on the do-
nation rate has been discussed controversially. In Switzer-
land, the “opt-in” or “informed consent” version implies
that donation can only be done if the patient has previously
agreed to donation and recorded it in a donation card or,
if this is not the case, the relatives give their consent. Cur-
rently, only 5% of patients carry a donation card. There-
Figure 4: Long-term survival of the first 133 patients transplanted
in Zurich from the restart of the programme in 1985 until 1991.
fore, in the vast majority of cases, the relatives have to de-
cide about organ donation of a loved one. But more than
50% of the relatives do not know the willingness of the
patient to donate. This leads to a more than 50% refusal
rate by the relatives of potential organ donors [47]. If the
population could be encouraged to document their willing-
ness or unwillingness to donate, the donation rate would
probably rise, since, according to a representative survey in
2015, 85% of the Swiss population are in favour for organ
donation. To increase the documentation rate, Swisstrans-
plant decided to found a Swiss national organ donor reg-
istry which was implemented in October 2018. Within 3
months, 40000 people registered as potential donors [47].
In contrast to the “opt-in” consent, the “presumed consent“
or “opt-out consent” implies that people may become po-
tential organ donors if they have neither explicitly refused
organ donation nor documented their unwillingness to do-
nate in a registry during their lifetime. In March 2019, an
initiative was filed to the Swiss government that advocates
for the change to an extended version of the presumed con-
sent, the so-called “soft opt-out consent” [47]. Adoption of
this concept means that the relatives are still asked for con-
sent even though presumed consent could be considered if
the deceased person has not rejected organ donation during
their lifetime. The Federal Council supports the initiative
and suggests a change in the transplant law that was enact-
ed in 2007. The Ministry of Internal Affairs will elaborate
a proposal that will be discussed on several political levels
before the parliament votes on it.
Swisstransplant anticipates that the change from informed
consent to presumed consent increases the donation rate
from 18.6 per million people (pmp) in 2018 to more than
20 pmp. Other European countries, such as Spain and Aus-
tria, which have adopted the concept of presumed consent,
achieved donation rates as high as 46.9 pmp in Spain and
23.5 pmp in Austria in 2017 [48, 49].
Donation after cardiocirculatory-determined death has
been shown to achieve successful results in transplantation
of organs such as kidneys, livers and lungs [50–53]. In
recent years, DCD programs have also been established
in heart transplantation. The outcomes can compete with
those following transplantation from brain dead donors [4,
54]. As in transplantation of other solid organs, DCD heart
transplantation may become a tool to expand the donor
pool. Following the successes of the teams in England
and Australia, other countries may be encouraged to im-
plement such programmes. The Swisstransplant working
group “Heart”, of which the corresponding author of this
article is the current president, is currently in the process
of evaluating the implementation of DCD heart transplan-
tation in Switzerland.
Other current aspects of heart transplantation include the
increasing number of recipients on ventricular assist sys-
tems, the growth in numbers of sensitised patients and
the morbidities that develop over the long-term following
heart transplantation, such as cardiac allograft vasculopa-
thy and malignancy, which have a significant impact on
outcome [36]. The discussion of these issues, however,
goes beyond the focus of this article.
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